Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials

Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis

(2020) Simpson Marion et al.   Multiple Sclerosis and Related Disorders

Effect of dalfampridine on information processing speed impairment in multiple sclerosis

(2019) Laura De Giglio et al.   NEUROLOGY

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis

(2019) Jianzhen Shi et al.   PLoS One

Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis

(2019) Maxime Valet et al.   CNS DRUGS

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

(2018) X. Montalban et al.   EUROPEAN JOURNAL OF NEUROLOGY

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Cognition in multiple sclerosis

(2018) James F. Sumowski et al.   NEUROLOGY

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

(2018) Jeremy Hobart et al.   CNS DRUGS

Multiple sclerosis - a review

(2018) R. Dobson et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.

(2018) C. Arreola-Mora et al.   Multiple Sclerosis and Related Disorders

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

Reliability, precision, and clinically important change of the Nine-Hole Peg Test in individuals with multiple sclerosis

(2017) Mario Hervault et al.   INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS

(2017) Sarah A. Morrow et al.   Multiple Sclerosis and Related Disorders

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study

(2016) Laure Peyro Saint Paul et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Pediatric multiple sclerosis

(2016) Maria Pia Amato et al.   NEUROLOGY

Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study

(2016) H.B. Jensen et al.   Multiple Sclerosis and Related Disorders

Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients

(2015) Katja Pavsic et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life

(2015) Etienne Allart et al.   JOURNAL OF NEUROLOGY

Home-based training to improve manual dexterity in patients with multiple sclerosis: A randomized controlled trial

(2015) Christian P Kamm et al.   Multiple Sclerosis Journal

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial

(2015) Raymond Hupperts et al.   Multiple Sclerosis Journal

Home-based training to improve manual dexterity in patients with multiple sclerosis: A randomized controlled trial

(2015) Christian P Kamm et al.   Multiple Sclerosis Journal

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial

(2015) Raymond Hupperts et al.   Multiple Sclerosis Journal

Hand dexterity and direct disease related cost in multiple sclerosis

(2014) Marcus W. Koch et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS

(2013) J. Hobart et al.   NEUROLOGY

Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study

(2013) Anat Achiron et al.   PLoS One

4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review

(2013) Henrik Boye Jensen et al.   Therapeutic Advances in Neurological Disorders

Dalfampridine: A Medication to Improve Walking in Patients with Multiple Sclerosis

(2012) Theodore E Pikoulas et al.   ANNALS OF PHARMACOTHERAPY

Limb Apraxia in Multiple Sclerosis: Prevalence and Impact on Manual Dexterity and Activities of Daily Living

(2012) Christian P. Kamm et al.   ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION

Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis

(2012) Laura Julian et al.   JOURNAL OF CHILD NEUROLOGY

Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study

(2012) Sarah A. Morrow et al.   JOURNAL OF NEUROLOGY

Assessing walking disability in multiple sclerosis

(2012) Bernd C. Kieseier et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

L-amphetamine improves memory in MS patients with objective memory impairment

(2011) James F Sumowski et al.   Multiple Sclerosis Journal

The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue

(2011) S Huolman et al.   Multiple Sclerosis Journal

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial

(2009) Sarah A. Morrow et al.   JOURNAL OF NEUROLOGY

Cognitive Dysfunction in Multiple Sclerosis: Methods and Prevalence from the GEDMA Study

(2008) J. Olazarán et al.   EUROPEAN NEUROLOGY